Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3K4FY)

• Drug Name: TG-1801 Drug Info
• Synonyms: NI-1701

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM3K4FY

Molecule-Related Drug Atlas

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[5]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[6]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[7]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[8]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[9]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[10]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[11]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[12]

Drug(s) Targeting Leukocyte surface antigen CD47 (CD47)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hu5F9-G4	DMBER0Q	Myelodysplastic syndrome	2A37	Phase 3	[13]
Evorpacept	DMJTX7Q	Gastric cancer	2B72	Phase 2/3	[14]
PF-07901801	DMEVYHR	Diffuse large B-cell lymphoma	2A81	Phase 2	[15]
ALX148	DMGQX0U	Myelodysplastic syndrome	2A37	Phase 1/2	[13]
DSP-107	DM8K0PR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[16]
AO-176	DMXU98C	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[18]
TTI-621	DMDNPAV	Haematological malignancy	2B33.Y	Phase 1	[19]
TTI-622	DMOCQ4K	Lymphoma	2A80-2A86	Phase 1	[20]
IBI188	DMXUJ1P	Myelodysplastic syndrome	2A37	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Not Available	[2]
Leukocyte surface antigen CD47 (CD47)	TT28S46	CD47_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT03804996) Study of TG-1801 in Subjects With B-Cell Lymphoma. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of TG Theraputics.
• [3] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [9] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [10] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [11] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [12] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-1751.
• [15] ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
• [16] Clinical pipeline report, company report or official report of KAHR Medical.
• [17] Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
• [18] Clinical pipeline report, company report or official report of Shattuck Labs.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] Clinical pipeline report, company report or official report of Trillium Therapeutics.
• [21] Clinical pipeline report, company report or official report of Innovent Biologics.